Intuitive: The Incumbent J&J Is AttackingThin moat
Johnson & Johnson (JNJ) — moat facet
In robotic surgery J&J is the challenger, entering against an incumbent with the installed base J&J enjoys everywhere else.
In soft-tissue robotic surgery the roles are reversed: J&J is the newcomer and the incumbent is Intuitive, whose da Vinci system has had the market largely to itself. On 22 July 2026 J&J received FDA de novo authorisation for its Ottava robotic surgery system to perform multiple procedures in general surgery1. MedTech Dive described Ottava as a second heavyweight challenger to Intuitive's da Vinci, following Medtronic's FDA clearance in late 20252.
J&J's approach differs from Intuitive's. Ottava integrates the robotic arms into the operating table and, according to J&J, takes up 30% to 50% less space than boom- and cart-mounted systems3. The authorisation covers ten procedures, including gastric bypass, gallbladder removal and hernia repair, and a trial is under way in inguinal hernia4. It came six months after the submission5.
The analysts quoted were sceptical. A J.P. Morgan analyst expected Intuitive to see very modest or immaterial market share loss, and Stifel noted the launch would take a deliberate and phased approach with significant training required6. J&J itself said it would launch with select United States customers7.
This is where J&J's size helps least. An installed base of robots, trained surgeons and hospital programmes built around them is exactly the kind of moat J&J enjoys in electrophysiology, and here it belongs to the other side. J&J's advantage is its surgical franchise: it already sells $10,137 million a year of surgical products into the same operating rooms8.
J&J is not alone in the challenge. MedTech Dive noted that a wave of smaller companies, including CMR Surgical, Distalmotion and Moon Surgical, are also launching robotic systems in the United States, giving Intuitive its first competition in more than two decades9. Being one of several challengers makes J&J's task harder and Intuitive's easier: the incumbent needs only to keep its base while the challengers split the rest.
J&J enters as a thin challenger to a wide incumbent. Ottava placements, once J&J reports them, will be the real score; until then, the United States surgery franchise's growth rate, 5.0% in the second quarter of 202610, is the nearest measure of whether the robot is pulling instruments through.
Ottava was authorised in July 2026; J&J now has a product in the market.
The nearest measure of Ottava pulling surgical products through until placements are reported.
Source: Johnson & Johnson Q2 2026 financial schedules ↗- ReportedOn 22 July 2026 J&J received FDA de novo authorisation for its Ottava robotic surgery system to perform multiple procedures in general surgery.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedMedTech Dive described Ottava as a second heavyweight challenger to Intuitive's da Vinci, following Medtronic's FDA clearance in late 2025.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedOttava integrates the robotic arms into the operating table and, according to J&J, takes up 30% to 50% less space than boom- and cart-mounted systems.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedThe authorisation covers ten procedures, including gastric bypass, gallbladder removal and hernia repair, and a trial is under way in inguinal hernia.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedIt came six months after the submission.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedA J.P. Morgan analyst expected Intuitive to see very modest or immaterial market share loss, and Stifel noted the launch would take a deliberate and phased approach with significant training required.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedJ&J itself said it would launch with select United States customers.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedJ&J's advantage is its surgical franchise: it already sells $10,137 million a year of surgical products into the same operating rooms.Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: MedTech segment and franchise sales analysis. — FY2025 · publ. 11 February 2026 · source ↗
- ReportedMedTech Dive noted that a wave of smaller companies, including CMR Surgical, Distalmotion and Moon Surgical, are also launching robotic systems in the United States, giving Intuitive its first competition in more than two decades.MedTech Dive, J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive. — July 2026 · publ. 22 July 2026 · source ↗
- ReportedOttava placements, once J&J reports them, will be the real score; until then, the United States surgery franchise's growth rate, 5.0% in the second quarter of 2026, is the nearest measure of whether the robot is pulling instruments through.Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - MedTech segment and franchise sales by region. — Q2 2026 · publ. 15 July 2026 · source ↗